Part 8 of the PUR-FORM MUSE Cell Series
What may happen from infusion to injured tissue and why the journey matters
In the last article, we asked a practical question: what is actually in the vial?
Cell count matters, but so do cell identity, viability, potency, manufacturing, and the proportion of cells that truly possess the biology we are trying to deliver.
The next question is:
What happens after those cells enter the bloodstream?
An IV infusion may look simple. The cells enter through a vein, the infusion ends, and the patient goes home.
Biologically, however, that is only the beginning.
For an intravenously administered MUSE cell to contribute meaningfully to repair, several things may need to happen in sequence. It must navigate the circulation, pass through or around the pulmonary microvasculature, recognize injury signals, interact with the vessel wall, enter damaged tissue, survive there, and then begin communicating with the surrounding environment.
IV cell therapy is not a single event. It is a biological journey.
Step 1: Entering the Circulation
Within moments of IV administration, MUSE cells enter an environment very different from the laboratory vial.
They are now traveling through moving blood, surrounded by red blood cells, platelets, plasma proteins, immune cells, and the endothelial lining of the vascular system.
This matters because a cell is not simply a drug dissolved in fluid. It is a living physical structure.
Its size, deformability, surface receptors, activation state, and interactions with vascular endothelium can influence where it travels and how long it remains there.
After a peripheral IV infusion, one of the first major vascular beds the cells encounter is the lung.
The Lung Is the First Major Checkpoint
The pulmonary circulation contains an enormous network of very small capillaries.
When relatively large cells are administered intravenously, some may be temporarily retained within this microvascular network, a phenomenon known as the pulmonary first-pass effect.
MUSE cells in peripheral blood and suspension culture have been reported in the range of roughly 10 to 15 micrometers.
Conventional culture-expanded MSCs are often larger, although their size varies substantially with source and culture conditions.
That physical difference may influence pulmonary passage, but size is not the whole explanation.
- Cell deformability matters.
- Adhesion molecules matter.
- Dose and infusion conditions matter.
- Manufacturing and cryopreservation may matter.
- The condition of the patient’s pulmonary microcirculation may matter as well.
MUSE cells should not be described as simply “bypassing” the lungs. Pulmonary passage is a biologic filter, not an on-off switch.
Why More Cells Do Not Automatically Mean Better Delivery
This helps explain why simply increasing the number of cells in an IV does not necessarily guarantee that more cells will reach the target tissue.
If a larger dose results mainly in greater microvascular retention, the additional cells may not translate into greater delivery to the injured organ.
The most meaningful dose may therefore be different from the number printed on the bag.
What ultimately matters is how many biologically competent cells remain functional, circulate, and reach tissue where they can act.
Step 2: Recognizing That an Injury Exists
Once cells are circulating, another problem appears:
How does a MUSE cell distinguish healthy tissue from damaged tissue?
This brings us back to one of the most important pathways in MUSE biology: S1P-S1PR2 signaling.
Damaged tissue can alter sphingosine-1-phosphate, or S1P, levels, and MUSE cells express the S1PR2 receptor.
Experimental work has shown that blocking this pathway markedly reduces MUSE-cell homing to injured tissue.
S1P acts like the beacon. S1PR2 acts like the antenna.
The cell is not consciously searching for damage.
It is responding to a chemical gradient.
When injury-associated signaling becomes stronger in one direction, receptor signaling can help guide cellular movement toward that source, a process called chemotaxis.
Step 3: Homing Is More Than Floating Toward the Injury
The word homing makes the process sound almost effortless.
It is not.
A circulating cell that reaches the correct vascular territory still has to interact with the endothelium, the thin layer of cells lining the inside of blood vessels.
The cell may slow, interact with adhesion molecules, attach to the endothelial surface, and then move across the vessel wall into the surrounding tissue.
This movement out of the circulation is often called transmigration or extravasation.
Recognize the signal → move toward it → interact with the vessel wall → cross the endothelium → enter damaged tissue
Step 4: Reaching the Tissue Creates a New Problem: Survival
Once a MUSE cell leaves the circulation, it reaches the same environment that generated the distress signal.
- Damaged tissue can be profoundly hostile.
- Oxygen may be low.
- Oxidative stress may be high.
- Inflammation may be intense.
- Perfusion may be poor.
- The extracellular matrix may be disrupted or fibrotic.
This is where the stress-enduring part of the MUSE name becomes relevant.
Laboratory and preclinical studies suggest that MUSE cells tolerate several forms of cellular stress better than most non-MUSE mesenchymal cells.
Finding the injury matters only if the cell can remain functional after it arrives.
Step 5: The Cell Begins to Communicate
Survival is not the endpoint.
If the MUSE cell remains viable and functional, it can begin interacting with the injured environment through its secretome, the collection of signaling molecules released by the cell.
These signals can include soluble proteins, cytokines, growth factors, lipids, and extracellular vesicles.
They may influence immune activity, inflammation, cell survival, blood-vessel biology, extracellular-matrix remodeling, and neighboring cells.
This may be one of the most important features of a living regenerative cell:
It does not simply arrive. It can sense its surroundings and alter its communication in response to the environment it encounters.
Step 6: Does the Cell Stay?
Another major question is how long the cell remains in the tissue.
There is no single answer.
Persistence likely depends on the disease, the degree of injury, the immune environment, the cell preparation, and the individual patient.
Some biological effects might occur even if cells remain only briefly because signaling can begin rapidly.
Longer persistence could allow more extensive interaction with local tissue.
If some cells integrate into damaged tissue, the biological possibilities change again.
Persistence is therefore better thought of as a spectrum than as an all-or-nothing event.
Step 7: Can MUSE Cells Become Part of the Tissue?
One characteristic that distinguishes MUSE cells from many conventional MSC populations is their reported capacity for tissue-compatible differentiation.
In preclinical models, MUSE cells that reach damaged organs have expressed characteristics associated with neural, cardiac, hepatic, vascular, and other tissue lineages.
That should not be interpreted as meaning an IV infusion simply rebuilds an organ.
A more realistic model is that several mechanisms may occur together.
- Some cells may communicate through the secretome.
- Some may regulate inflammation.
- Some may influence the extracellular matrix or vascular environment.
- Some may persist.
- And some may move toward tissue-compatible differentiation.
The relative importance of those pathways probably varies with the injury.
What Happens Over Time?
For patients, it is useful to think of the journey in broad phases rather than as a precise biological clock.
Minutes: Cells enter the bloodstream and encounter the pulmonary circulation.
Minutes to hours: Some cells continue into systemic circulation, where injury-associated signals may begin influencing their distribution.
Hours: Cells reaching the appropriate vascular territory may interact with endothelium and potentially enter damaged tissue.
Hours to days: Cells within the tissue must tolerate inflammation, hypoxia, oxidative stress, and other environmental challenges.
Days: Paracrine signaling, immune modulation, and interaction with the local microenvironment may become increasingly important.
Days to weeks: Persistent cells may continue communicating with tissue. Experimental models suggest some may participate in tissue-compatible differentiation or integration.
Weeks to months: The clinically important question is whether those early cellular events translate into meaningful and durable changes in tissue function.
This timeline is conceptual. Every disease, tissue, cell product, and patient is different.
Route Matters
The journey also helps explain why route of administration matters.
A cell placed directly into a joint does not face the same biological journey as an IV cell.
Local delivery begins near the target tissue.
IV delivery provides systemic access but requires successful navigation of the circulation and response to injury signals.
Neither approach is automatically superior.
The better question is:
What route best matches the biological problem we are trying to treat?
The Patient Is Part of the Journey
Even when two patients receive the same cell product, the cells do not enter the same biological environment.
One patient may have substantial inflammation.
Another may have endothelial dysfunction.
Another may have poor perfusion, oxidative stress, or fibrosis.
This is why regenerative therapy is best viewed as a two-sided equation:
The quality of the cell product on one side and the condition of the host environment on the other.
A potent cell is only part of the equation. The environment into which we place it matters too.
From IV Bag to Biological Response
So what happens after MUSE cells are administered intravenously?
Potentially, a great deal.
The cells must enter the circulation, negotiate the pulmonary microvasculature, remain functional, detect signals associated with tissue injury, reach the appropriate vascular territory, interact with and cross the endothelium, survive within damaged tissue, and then communicate with their surroundings.
Some cells may persist, integrate, or differentiate.
Others may exert their effects primarily through signaling.
And many infused cells will not necessarily complete every step.
That is an important point:
The IV infusion is only the delivery event. The therapeutic hypothesis depends on what the cells can do after the infusion ends.
Why MUSE Cells Make This Journey Particularly Interesting
MUSE cells are intriguing as an IV platform because several of their proposed properties fit different stages of this journey:
relatively small size, S1P-S1PR2 injury-directed homing, stress endurance, a biologically active secretome, immune-regulatory properties, and tissue-compatible differentiation in experimental systems.
Circulate → sense → home → enter → survive → signal → potentially integrate → support repair
That sequence does not mean every infused MUSE cell completes every step, and these mechanisms have not been proven equally well in every human disease.
But it helps explain why MUSE cells have generated so much interest as an intravenously delivered regenerative-cell platform. Pasted markdown
The Question That Really Matters
The IV bag tells us what we administer.
It does not tell us what reaches the injury, how long the cells remain functional, or what they do once they arrive.
So the most important questions in IV cell therapy may not simply be how many cells were infused.
- They are:
- How many remained functional?
- How many successfully navigated the circulation?
- How many reached the target tissue?
- How long did they persist?
- And what biological effects did they produce once they arrived?
Those questions are much harder to answer.
Ultimately, however, they will determine whether intravenous cell therapy can become meaningful regenerative medicine.
Dr. P
